Navigation Links
Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Date:4/5/2011

effective as vancomycin in clinical cure, and was superior to vancomycin in global cure, defined as cure without a recurrence after 4 weeks of therapy. The advisory committee referred to the global cure outcome as 30-day resolution, which we believe is indicative of DIFICID's benefit in reducing recurrences," said Sherwood Gorbach, M.D., Optimer's Chief Medical Officer. "While the advisory committee vote was split on how best to describe the recurrence benefit, the committee members overwhelmingly recognized that DIFICID at 30 days was superior to vancomycin. We appreciated the committee's discussion and look forward to working with the FDA as it considers our DIFICID NDA."

The AIDAC based its decision in part on the review of clinical evidence from the two largest, comparative Phase 3 clinical trials ever conducted against vancomycin in CDI. These multi-center, randomized, double-blind trials enrolled a total of 1,164 adults with confirmed CDI, who received either DIFICID (200 mg q12h) or vancomycin (125 mg q6h), the only FDA-approved product for the treatment of CDI. The objective of both studies was to show that a 10-day course of DIFICID was at least as efficacious (non-inferior) and safe as a 10-day course of vancomycin for the treatment of CDI. In both studies, DIFICID demonstrated a statistically significant reduction in the rate of recurrence compared with patients treated with vancomycin, reducing CDI recurrences by 47 percent, and was statistically superior to vancomycin in global cure rate (clinical cure without disease recurrence within four weeks). In addition, DIFICID met the primary endpoint of non-inferiority of clinical cure (defined as patients requiring no further CDI therapy two days after completion of study medication) compared to vancomycin.

DIFICID was safe and well tolerated in both studies, showing a similar incidence of treatment-related adverse events when compared to vancomycin.

Scheduled Conference Call


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
(Date:9/22/2014)... YORK , September 22, 2014 ... Market Report on "Global Market Study on Ophthalmic Devices: ... by 2020," the global ophthalmic devices market was valued at USD ... at a CAGR of 6.5% from 2014 to 2020, ... in 2020. Browse the full Global Market Study ...
(Date:9/22/2014)... -- AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), a ... announced today that they are starting production of the ... is designed for placement inside optical shops and Eye ... there are over 20,000 optical stores in America.  ... first automated kiosk dedicated to cleaning and sanitizing eyeglasses ...
Breaking Medicine Technology:Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2
... MARY, Fla., Jan. 26, 2012   In a pediatric ... caring environment, Middleton Pediatrics is one of the first ... to assess their young patients vision.  This revolutionary vision ... important vision data in one second or less.  ...
... 26, 2012  Aria Diagnostics, a molecular diagnostics company, ... study that examines the accuracy of its non-invasive ... (associated with Down syndrome) and Trisomy 18 (associated ... test, coupled with a proprietary algorithm to assess ...
Cached Medicine Technology:Middleton Pediatrics Now Using Spot to Screen Patients 2Middleton Pediatrics Now Using Spot to Screen Patients 3Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology 2
(Date:9/22/2014)... have developed a chip capable of simulating a ... system to test the effectiveness of nanoparticles and ... a tumor-microenvironment-on-chip (T-MOC) device, will allow researchers to ... barriers that prevent the targeted delivery of therapeutic ... professor of mechanical engineering., Researchers are trying to ...
(Date:9/22/2014)... Almost three-quarters (74%) of parents are aware of ... one-quarter (28%) have used those online ratings to ... to U-M research published today in Pediatrics ... Mott Children,s Hospital National Poll on Children,s Health, ... of physicians influenced their choices in seeking healthcare ...
(Date:9/22/2014)... 22, 2014 (HealthDay News) -- Metformin, a drug commonly ... low levels of thyroid-stimulating hormone (TSH) among patients with ... researchers cautioned that low TSH levels may be associated ... link was not established in this study. Among ... there were 495 incidences of low levels of thyroid-stimulating ...
(Date:9/22/2014)... 2014 “The Race is On!” for the ... Sunday, October 12, 2014 as it moves to its new ... As the signature fundraising and awareness event for Susan G. ... Phoenix Race for the Cure provides supporters of all ages ... and even sleeping in. , “Moving the Race to ...
(Date:9/22/2014)... A study led by University of North Carolina at ... the accurate diagnosis of people who are experiencing the ... delusions that define the development of severe mental disorders ... early adulthood and affects about 1 in every 100 ... person can be a life compromised, and the burden ...
Breaking Medicine News(10 mins):Health News:New chip promising for tumor-targeting research 2Health News:Online ratings influence parents' choices of physicians for their children 2Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Blood test may help determine who is at risk for psychosis 2
... , , PANAMA CITY, Fla., ... hospital, diligence of staff washing their hands when moving from patient ... The Joint Commission , handwashing failures contribute to ... and cost U.S. hospitals $4 billion to $29 billion annually to ...
... , , MINNEAPOLIS, ... officers, introduced new Board Members and thanked outgoing members for their ... General Counsel, Ltd., was elected as the new Board Chair. The ... , David Fisher, Board ...
... , SAN DIEGO, Sept. 16 ... device company, today announced that its application for premarket approval (PMA) ... approved by the Food and Drug Administration. The Company can now ... , Jim Hitchin, SpectraScience,s, CEO said, "We are pleased ...
... ... supplements at 9th Annual Conference on Protein Expression in Animal Cells (PEACe) in Jackson Hole, ... Fort ... well defined and regulatory friendly cell culture media supplements at the 9th Annual PEACe conference ...
... 16 Prime Staffing, a premier staffing services has achieved ... from The Joint Commission. , , Prime ... national standards addressing how staffing firms determine the qualifications and ... how they monitor staff,s performance. , , ...
... , LONDON, Sept. 16 McGraw-Hill Medical won ... Medical Book Competition awards ceremony, including two category first prize awards ... coveted award went to the ground-breaking Robotic Surgery: Theory and ... , , Speaking about the award, Dr Vivienne ...
Cached Medicine News:Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 2Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 3Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 4Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:SpectraScience Receives FDA Approval for Enhancements to WavSTAT(R) Optical Biopsy System 2Health News:InVitria Cell Culture Product Line to Headline PEACe 2Health News:Prime Staffing Awarded Certification from The Joint Commission 2Health News:McGraw-Hill Medical Wins 2009 BMA Medical Book of the Year Award 2
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
... concave seats and large backrests with lumbar ... armrests, and casters and glides. • Choose ... a variety of environments including: industry, education, ... and office. • With reinforced nylon base ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
Medicine Products: